Emerging role of GLP-1 agonists in cardio-metabolic therapy - Focus on Semaglutide
Semaglutide, a GLP-1 receptor agonist, has emerged as a promising agent in cardiovascular disease management, particularly for patients with obesity and diabetes. Recent studies have demonstrated significant benefits of Semaglutide beyond glycemic control, including reduced major adverse cardiovascu...
Saved in:
| Main Authors: | Celestine Odigwe, Rajasekhar Mulyala, Haijra Malik, Brent Ruiz, Mariam Riad, Mohammad As Sayiadeh, Sanchitha Honganur, Alexis Parks, Mustafeez Ur Rahman, Nasser Lakkis |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | American Heart Journal Plus |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666602225000217 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
by: Laura Opalska, et al.
Published: (2024-12-01) -
Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment
by: Rui Salvador, et al.
Published: (2025-03-01) -
Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years
by: Marwan Sabbagh, et al.
Published: (2025-04-01) -
Granuloma annulare after starting semaglutide
by: Tajena Jones, BS, et al.
Published: (2025-08-01) -
Cardiometabolic Modulation by Semaglutide Contributes to Cardioprotection in Rats with Myocardial Infarction
by: Yan H, et al.
Published: (2024-11-01)